UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 212

Sortiert nach

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Annals of oncology, 2018-10, Vol.29 (10), p.2052-2060

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

British journal of cancer, 2013-09, Vol.109 (6), p.1408-1413

2013

Link zum Volltext

Verfügbarkeit prüfen

Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells

Human gene therapy, 2005-08, Vol.16 (8), p.996-1005

2005

Link zum Volltext

Verfügbarkeit prüfen

Is sorafenib effective in colorectal cancer? Definition of resistance indicators and impact of potential comedications

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e14126-e14126

2011

Link zum Volltext

Verfügbarkeit prüfen

Quality-of-life assessment in patients with malignant ascites: Results of a multicenter phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.9113-9113

2011

Link zum Volltext

Verfügbarkeit prüfen

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS166-TPS166

2011

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the German AIO Pancreatic Cancer Group (AIO PK-0204)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4070-4070

2010

Link zum Volltext

Verfügbarkeit prüfen

Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS205-TPS205

2010

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel, oxaliplatin, and capecitabine (TEX regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): Results from a phase II trial of the German AIO group

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4099-4099

2010

Link zum Volltext

Verfügbarkeit prüfen

An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14503-e14503

2010

Link zum Volltext

Verfügbarkeit prüfen

Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4119-4119

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3583-3583

2011

Link zum Volltext

Verfügbarkeit prüfen

Toxicogenomic profiling of fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) in advanced gastric cancer: A translational study of the German Arbeitsgemeinschaft Internistische Onkologie (AIO)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14624-e14624

2010

Link zum Volltext

Verfügbarkeit prüfen

5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4013-4013

2010

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4077-4077

2011

Link zum Volltext

Verfügbarkeit prüfen

Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3504-3504

2011

Link zum Volltext

Verfügbarkeit prüfen

Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4070-4070

2011

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel, oxaliplatin, and capecitabine (TEX regimen) for patients with metastatic gastric cancer: Interim results from a phase II trial by the German AIO Group

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4554-4554

2009

Link zum Volltext

Verfügbarkeit prüfen

Erythropoetin (epoetin beta) once weekly in anemic patients with advanced cancer of the stomach or gastroesophageal junction: Interim results of a randomized German AIO phase II trail

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.15133-15133

2007

Link zum Volltext

Verfügbarkeit prüfen

CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase II study

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4064-4064

2004

Link zum Volltext

Verfügbarkeit prüfen

CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase II study

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4064-4064

2004

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

The New England journal of medicine, 2021-04, Vol.384 (13), p.1191-1203

2021

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer

Annals of oncology, 2016-01, Vol.27 (1), p.134-140

2016

Link zum Volltext

Verfügbarkeit prüfen

Spleen as homogenous calcified opacity in roentgenogram

Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1956-04, Vol.84 (4), p.491

1956

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 212

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Englisch
(151)
Deutsch
(60)
Japanisch
(12)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(56)
Humans
(50)
Male
(29)
Oncology
(28)
Biological And Medical Sciences
(26)
Female
(25)
Medical Sciences
(24)
Aged
(21)
Middle Aged
(21)
Prognosis
(17)
Adult
(16)
Multiple Myeloma
(16)
Hematology
(15)
Animals
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Physical Sciences
(11)
Tumors
(11)
Aged, 80 And Over
(9)
Disease-Free Survival
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells

Is sorafenib effective in colorectal cancer? Definition of resistance indicators and impact of potential comedications

Quality-of-life assessment in patients with malignant ascites: Results of a multicenter phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial

Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the German AIO Pancreatic Cancer Group (AIO PK-0204)

Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071)

Docetaxel, oxaliplatin, and capecitabine (TEX regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): Results from a phase II trial of the German AIO group

An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer

Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC)

Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205

Toxicogenomic profiling of fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) in advanced gastric cancer: A translational study of the German Arbeitsgemeinschaft Internistische Onkologie (AIO)

5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data

Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial

Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Docetaxel, oxaliplatin, and capecitabine (TEX regimen) for patients with metastatic gastric cancer: Interim results from a phase II trial by the German AIO Group

Erythropoetin (epoetin beta) once weekly in anemic patients with advanced cancer of the stomach or gastroesophageal junction: Interim results of a randomized German AIO phase II trail

CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase II study

CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase II study

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Prognostic factors for progression-free and overall survival in advanced biliary tract cancer

Spleen as homogenous calcified opacity in roentgenogram

Aktive Filter

Suchergebnisse filtern